🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

US epidemic of sexually transmitted infections shows signs of slowing, CDC says

Published 11/12/2024, 11:54 AM
Updated 11/12/2024, 01:25 PM
© Reuters. FILE PHOTO: A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell/File Photo

By Mariam Sunny

(Reuters) - The number of sexually transmitted infections (STI) in the United States in 2023 was down nearly 2% from the year before, a sign the epidemic could be slowing, the Centers for Disease Control and Prevention said on Tuesday.

More than 2.4 million STIs were reported last year, compared to more than 2.5 million in 2022, with nearly half occurring in adolescents and young adults aged 15–24, according to a report by the agency.

The findings provide a "glimmer of hope" that the "tide is turning" after nearly two decades of increasing STI rates, Jonathan Mermin, Director of CDC's National Center for HIV, Viral Hepatitis, STD, and TB Prevention, said in a statement.

"It's been a long time since we have seen declines in STI rates, and so I am encouraged by this, but there's still a long way to go to... fully address the STI epidemic," said Laura Bachmann of CDC's Division Of Sexually Transmitted Disease And Prevention.

Chlamydia was the most common nationally notifiable STI in the United States in 2023, with more than 1.6 million cases. That rate was similar to the previous year, but was 6.2% lower than the Chlamydia incidence in 2018.

Gonorrhea cases dropped 7.7% from 2022 to 2023, and fell below pre-pandemic levels.

The most infectious stages of syphilis, known as primary and secondary syphilis, decreased 10.7% in 2023, marking the first substantial decrease since 2001, the report said.

Increases in newborn syphilis, transmitted from mother-to-child during pregnancy, appear to be slowing in some areas, the CDC said. The number of cases rose 3% in 2023, compared to 30% annual increases in prior years.

Still, in 2023, more than a million more STIs were reported than in 2003, and nearly 4,000 babies were born with syphilis, the CDC said.

Data collection during the pandemic was difficult and potentially less reliable than usual, the CDC said.

Stigma is one of the biggest barriers to addressing the STI epidemic, potentially impacting individuals' willingness to be screened and providers' willingness to inquire about sexual history, Bachmann said.

The epidemic disproportionately affects American Indian, African American, and Hispanic communities, as well as gay and bisexual men, the report said.

The agency said the improvements follow advancements in STI prevention, including use of antibiotics to prevent certain bacterial STIs and authorized at-home tests to detect the infection.

© Reuters. FILE PHOTO: A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell/File Photo

The U.S. Food and Drug Administration in August approved the first at-home, over-the-counter test to detect syphilis antibodies in human blood developed by privately held NOWDiagnostics.

(This story has been corrected to rectify the spelling of a CDC official's name in paragraphs 4 and 11)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.